Context Therapeutics, Inc. is focused on developing innovative treatments for hormone-driven breast and gynecological cancers. Their lead candidate, ONA-XR, aims to be a complete antagonist of the progesterone receptor. Founded in 2015, the company is headquartered in Philadelphia, PA.